NFE2L2 and neoplasm: Among these, KEAP1 mutations result in the constitutive activation of nuclear factor erythroid 2-related factor 2 (NRF2, also known as NFE2L2), which has been associated with tumor malignancy and drug resistance, leading to poor prognosis [22].